Gate Bioscience Seals $856M Collaboration with Lilly
Deal News | Jul 28, 2025 | Wilmer Cutler Pickering Hale and Dorr LLP
Gate Bioscience, a biotechnology firm focused on developing molecular gate drugs, has entered into a high-value collaboration and license agreement with Eli Lilly and Company. The partnership aims to explore novel therapeutics capable of eliminating disease-causing proteins, expanding the potential to treat diseases with significant medical needs. Through this agreement, Gate is set to receive a substantial upfront payment, equity investment, along with potential milestone payments that could ultimately value the deal at $856 million. WilmerHale, with its team led by Partner Jekkie Kim and other experts, acted as advisors for Gate Bioscience, covering corporate, tax, regulatory, and competition aspects of the deal.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Both Gate Bioscience and Eli Lilly are based in the United States, and the advisory firm WilmerHale is also located there.
Industry
- Biotechnology – The article is about a collaboration within the biotechnology sector, focusing on molecular gate therapeutics.
- Pharmaceuticals – Eli Lilly operates within the pharmaceutical sector, relevant due to its involvement in developing and commercializing new therapeutics.
Financials
- $856 million – The total potential value of the collaboration and license agreement between Gate Bioscience and Eli Lilly.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Gate Bioscience | Target Company | Company | Gate Bioscience is a biotechnology company focusing on molecular gate therapeutics. |
| Eli Lilly and Company | Bidding Company | Company | Eli Lilly is a global pharmaceutical company entering into an agreement with Gate Bioscience. |
| WilmerHale | Legal Advisor | Company | WilmerHale provided legal advisory services to Gate Bioscience for this transaction. |